semaglutide and anaesthesia Your patient took this week. Cancel the EGD, proceed, or risk-stratify? The OCULUS randomized trial found clinically significant residual gastric volume was higher when GLP-1/GIP agonists were continued vs held for A very important and practice-changing

However, commercial transdermal peptide products remain limited, and preparation requires specialized equipment beyond what typical researchers possess

Start todayMore Info Potential Weight Loss* Administration methods** Oral Drops Injections Lozenges Dose frequency*** Weekly or Daily Potential side effects Possible side effects may include nausea, vomiting, constipation, diarrhea, indigestion or stomach discomfort, reduced appetite, headache, fatigue, or injection site reactionsespecially when starting or increasing the dose

Others prefer evening application when they have more time for proper application

Cost-effectiveness of laparoscopic gastric banding and bypass for morbid obesity

Taking breaks typically leads to weight regain without providing any demonstrated safety advantage